Shenzhen Weiguang Biological Products Co Ltd Total Liabilities
Shenzhen Weiguang Biological Products Co Ltd total liabilities. Based on the latest financial reports, Shenzhen Weiguang Biological Products Co Ltd (002880) has total liabilities worth CN¥1.19 Billion CNY (≈ $174.34 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002880 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shenzhen Weiguang Biological Products Co Ltd (2012–2025)
Total liabilities of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2025. This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Shenzhen Weiguang Biological Products Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Weiguang Biological Products Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Youdao Inc
NYSE:DAO
|
USA | $3.91 Billion |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
China | CN¥4.17 Billion |
|
Zhongsheng Group Holdings Limited
F:5Z0
|
Germany | €60.19 Billion |
|
Guangdong Champion Asia Electronics Co Ltd
SHG:603386
|
China | CN¥2.42 Billion |
|
DAKOTA GOLD CORP. DL-001
F:RR6
|
Germany | €4.00 Million |
|
GuangDong Rifeng Electric Cable Co Ltd
SHE:002953
|
China | CN¥1.80 Billion |
|
Naphtha
TA:NFTA
|
Israel | ILA3.16 Billion |
|
Birla Corporation Limited
NSE:BIRLACORPN
|
India | Rs69.73 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Shenzhen Weiguang Biological Products Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002880 asset base.
Liquidity & Leverage Metrics
Shenzhen Weiguang Biological Products Co Ltd Total Liabilities Ratios Explained
Shenzhen Weiguang Biological Products Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Weiguang Biological Products Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Weiguang Biological Products Co Ltd (2012–2025)
The table below shows the annual total liabilities of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.29 Billion ≈ $189.49 Million |
+22.95% |
| 2024-12-31 | CN¥1.05 Billion ≈ $154.12 Million |
+26.72% |
| 2023-12-31 | CN¥831.14 Million ≈ $121.62 Million |
+17.36% |
| 2022-12-31 | CN¥708.20 Million ≈ $103.63 Million |
+229.04% |
| 2021-12-31 | CN¥215.23 Million ≈ $31.49 Million |
+1.35% |
| 2020-12-31 | CN¥212.36 Million ≈ $31.08 Million |
+55.42% |
| 2019-12-31 | CN¥136.64 Million ≈ $19.99 Million |
-11.00% |
| 2018-12-31 | CN¥153.53 Million ≈ $22.47 Million |
-10.49% |
| 2017-12-31 | CN¥171.52 Million ≈ $25.10 Million |
-57.48% |
| 2016-12-31 | CN¥403.44 Million ≈ $59.04 Million |
-12.72% |
| 2015-12-31 | CN¥462.25 Million ≈ $67.64 Million |
+0.33% |
| 2014-12-31 | CN¥460.73 Million ≈ $67.42 Million |
-5.76% |
| 2013-12-31 | CN¥488.91 Million ≈ $71.54 Million |
-7.86% |
| 2012-12-31 | CN¥530.63 Million ≈ $77.65 Million |
-- |
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection fre… Read more